News

UCD is a rare and life-threatening condition caused by an inherited inborn error of metabolism. Current treatment options are associated with poor outcomes. “The rare pediatric disease designation

In May 2018, Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) entered into an initial agreement to develop and commercialise Korsuva to treat CKD-aP in haemodialysis

The round was led by SR One and Taiho Ventures, LLC , with participation from existing investors 8VC and Mission BioCapital and new investors including BVF Partners L.P.,

Venclexta was previously granted provisional approval in this setting under the FDA’s accelerated approval program in November 2018. Today’s FDA approval converts Venclexta’s accelerated approval in this setting

The approval from an Indian regulator allows conducting an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in the country. According to RDIF, the multi-centre and

Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial

The approval is based on results from the Phase 3 KEYNOTE-204 trial in which KEYTRUDA significantly reduced the risk of disease progression or death by 35% (HR=0.65 [95%

The deal also allows Disarm equity-holders to secure up to $1.225bn in additional future payments for potential development, regulatory and commercial milestones based on the successful development and

The human adenovirus (hAd5) vector vaccine candidate has been designed to target both the inner nucleocapsid (N) and outer spike (S) proteins, said ImmunityBio. The N-protein has been